Increasing Dosage of Leucovorin Results in Pharmacokinetic and Gene Expression Differences When Administered as Two-Hour Infusion or Bolus Injection to Patients with Colon Cancer.

LC-MS/MS bolus injection colon cancer gene expression leucovorin methylenetetrahydrofolate pharmacokinetics two-hour infusion

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
30 Dec 2022
Historique:
received: 01 12 2022
revised: 26 12 2022
accepted: 28 12 2022
entrez: 8 1 2023
pubmed: 9 1 2023
medline: 9 1 2023
Statut: epublish

Résumé

The combination of 5-fluorouracil (5-FU) and leucovorin (LV) forms the chemotherapy backbone for patients with colorectal cancer. However, the LV administration is often standardized and not based on robust scientific data. To address these issues, a randomized pharmacokinetics study was performed in patients with colon cancer. Thirty patients were enrolled, receiving 60, 200 or 500 mg/m

Identifiants

pubmed: 36612253
pii: cancers15010258
doi: 10.3390/cancers15010258
pmc: PMC9818718
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Swedish Cancer Society
ID : CAN 2015/499, CAN 2018/620, CAN 201025PjF
Organisme : King Gustav V Jubilee Clinic Foundation for Cancer Research
ID : 2016:70
Organisme : The Swedish State under the LUA/ALF agreement
ID : ALFGBG-426941, ALFGBG-586631, ALFGBG-723361, ALFGBG-788901, ALFGBG-966007
Organisme : The Swedish Society of Medicine
ID : SLS-689001
Organisme : The Assar Gabrielssons Foundation
ID : FB17-82
Organisme : The Inga-Britt and Arne Lundberg Foundation
ID : 335/07

Références

Arch Biochem Biophys. 2003 Feb 1;410(1):161-6
pubmed: 12559989
Arch Biochem Biophys. 2007 Feb 15;458(2):194-201
pubmed: 17250800
Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15163-8
pubmed: 21876188
J Clin Oncol. 1992 Jun;10(6):896-903
pubmed: 1534121
Drug Metab Dispos. 2015 Jan;43(1):93-9
pubmed: 25349122
Expert Rev Mol Med. 2009 Jan 28;11:e4
pubmed: 19173758
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Biochem Pharmacol. 1989 Jan 15;38(2):335-42
pubmed: 2914018
Cancer Res. 1991 Jul 1;51(13):3476-81
pubmed: 2054787
Front Oncol. 2020 Apr 28;10:658
pubmed: 32411609
Biochem Pharmacol. 2003 Mar 1;65(5):765-71
pubmed: 12628490
Annu Rev Nutr. 2018 Aug 21;38:219-243
pubmed: 30130467
J Biol Chem. 2014 Oct 17;289(42):29386-96
pubmed: 25164808
Biomed Chromatogr. 2013 Apr;27(4):487-95
pubmed: 22991184
Br J Clin Pharmacol. 1994 Mar;37(3):243-8
pubmed: 8198932
Am J Physiol. 1992 Jan;262(1 Pt 1):G150-8
pubmed: 1733262
Cancer Res. 2013 Mar 1;73(5):1524-35
pubmed: 23288510
Cancer Chemother Pharmacol. 2014 Dec;74(6):1167-74
pubmed: 25238909
Pharm Res. 2010 Apr;27(4):665-72
pubmed: 20148291
Ann Oncol. 2012 Oct;23(10):2479-2516
pubmed: 23012255
J Biol Chem. 1996 May 31;271(22):13077-87
pubmed: 8662720
J Nutr Biochem. 2015 Oct;26(10):1084-94
pubmed: 26168702
Crit Rev Oncol Hematol. 2016 Oct;106:118-31
pubmed: 27637357
Br J Cancer. 2002 Aug 12;87(4):393-9
pubmed: 12177775
Biochem Pharmacol. 1979 Oct 1;28(19):2993-7
pubmed: 518696
Biochem Biophys Res Commun. 2008 Jan 25;365(4):801-7
pubmed: 18035049
Biochim Biophys Acta. 1995 May 12;1266(3):245-9
pubmed: 7766710
J Natl Cancer Inst. 1990 Sep 5;82(17):1411-5
pubmed: 2388292
Clin Colorectal Cancer. 2015 Mar;14(1):1-10
pubmed: 25579803
Pharmacol Ther. 2000 Mar;85(3):207-15
pubmed: 10739875
Biochem Pharmacol. 1995 Mar 1;49(5):677-85
pubmed: 7534077
Invest New Drugs. 1989 Apr;7(1):27-36
pubmed: 2500406
J Biol Chem. 2002 Oct 11;277(41):38381-9
pubmed: 12161434
Cancer Chemother Pharmacol. 2010 Mar;65(4):735-42
pubmed: 19636555
J Biol Chem. 2003 Aug 8;278(32):29856-62
pubmed: 12764149
J Biol Chem. 2008 Jul 25;283(30):20687-95
pubmed: 18499665
Biochem Pharmacol. 1995 Oct 26;50(9):1347-51
pubmed: 7503782
Cancer Chemother Pharmacol. 1994;34(6):491-6
pubmed: 7522978
Biochemistry. 1978 Sep 19;17(19):4018-24
pubmed: 101234
J Cancer. 2020 Apr 25;11(14):4213-4221
pubmed: 32368304
Cell. 2006 Dec 1;127(5):917-28
pubmed: 17129779
J Cell Mol Med. 2010 Apr;14(4):771-94
pubmed: 20015196
Biochem J. 2001 Feb 15;354(Pt 1):115-22
pubmed: 11171086
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Transl Oncol. 2019 Nov;12(11):1461-1467
pubmed: 31421459
Am J Clin Nutr. 2007 Jul;86(1):159-66
pubmed: 17616776
J Clin Oncol. 2003 Oct 15;21(20):3721-8
pubmed: 12963704

Auteurs

Helena Taflin (H)

Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, Sahlgrenska Academy at University of Gothenburg, 41685 Gothenburg, Sweden.
Transplant Center, Sahlgrenska University Hospital, 41345 Gothenburg, Sweden.

Elisabeth Odin (E)

Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, Sahlgrenska Academy at University of Gothenburg, 41685 Gothenburg, Sweden.

Göran Carlsson (G)

Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, Sahlgrenska Academy at University of Gothenburg, 41685 Gothenburg, Sweden.

Bengt Gustavsson (B)

Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, Sahlgrenska Academy at University of Gothenburg, 41685 Gothenburg, Sweden.

Yvonne Wettergren (Y)

Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, Sahlgrenska Academy at University of Gothenburg, 41685 Gothenburg, Sweden.

Elinor Bexe Lindskog (E)

Department of Surgery, Institute of Clinical Sciences, Sahlgrenska University Hospital, Sahlgrenska Academy at University of Gothenburg, 41685 Gothenburg, Sweden.

Classifications MeSH